Ofatumumab治疗移植后淋巴增生性疾病。

Q1 Medicine

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI:10.1016/j.hemonc.2020.04.004

Madhav Seshadri, Genevieve M Crane, Usama Gergis

{"title":"Ofatumumab治疗移植后淋巴增生性疾病。","authors":"Madhav Seshadri, Genevieve M Crane, Usama Gergis","doi":"10.1016/j.hemonc.2020.04.004","DOIUrl":null,"url":null,"abstract":"Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein-Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":" ","pages":"68-73"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.04.004","citationCount":"5","resultStr":"{\"title\":\"Ofatumumab for Post-Transplant Lymphoproliferative Disorder.\",\"authors\":\"Madhav Seshadri, Genevieve M Crane, Usama Gergis\",\"doi\":\"10.1016/j.hemonc.2020.04.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein-Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.\",\"PeriodicalId\":39226,\"journal\":{\"name\":\"Hematology/ Oncology and Stem Cell Therapy\",\"volume\":\" \",\"pages\":\"68-73\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.04.004\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology/ Oncology and Stem Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.hemonc.2020.04.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/ Oncology and Stem Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.hemonc.2020.04.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 5

摘要

移植后淋巴细胞增生性疾病(PTLD)包括实体器官或异体造血干细胞移植(HSCT)后出现的一系列异常淋巴细胞增殖，通常与eb病毒(EBV)感染有关。治疗通常包括利妥昔单抗，一种针对CD20的嵌合单克隆抗体。在这里，我们报告了一位56岁的女性，在同种异体HSCT后患有ebv相关的PTLD，她对美罗华不耐受。患者转而接受ofatumumab治疗，这是一种针对CD20的全人源单克隆抗体，对EBV病毒载量和淋巴结病变有显著的反应。对于不能耐受利妥昔单抗的患者，Ofatumumab可能是一个重要的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Ofatumumab for Post-Transplant Lymphoproliferative Disorder.

Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein-Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematology/ Oncology and Stem Cell Therapy Medicine-Hematology

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.